

10 July 2024

Notice under Section 708A of the Corporations Act

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) (OTCPINK: MDBIF) hereby gives this notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Act").

The Company has issued a total of 47,389,255 ordinary fully paid shares ("**Issued Shares**") being 46,989,255 ordinary fully paid shares at an issue price of \$0.025 approved by Shareholders at the General Meeting held on 5 July 2024 and 400,000 ordinary fully paid shares at an issue price of \$0.03 per share for consultant services.

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Act; and
3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:
 - a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
 - b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Securities.

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au